E2 ModerateModerate confidencePEM not requiredObservationalPeer-reviewedReviewed
Standard · 3 min
Characterization of pituitary function with emphasis on GH secretion in the chronic fatigue syndrome.
Moorkens, G, Berwaerts, J, Wynants, H et al. · Clinical endocrinology · 2000 · DOI
Quick Summary
This study examined hormone levels in 73 people with ME/CFS compared to 21 healthy people. Researchers found that people with ME/CFS had lower growth hormone (GH) levels, especially at night and when their body was stressed by low blood sugar. They also had higher levels of prolactin and thyroid-stimulating hormone (TSH), suggesting their brain chemistry may be imbalanced. These hormone changes were associated with increased belly fat in ME/CFS patients.
Why It Matters
This study provides quantitative evidence of neuroendocrine dysfunction in ME/CFS, particularly GH dysregulation, which may explain the fatigue, exercise intolerance, and metabolic changes patients experience. The findings support biological abnormalities in ME/CFS and suggest that the condition involves measurable alterations in brain-pituitary signaling rather than being purely psychological.
Observed Findings
GH response to insulin-induced hypoglycemia was significantly lower in CFS patients (peak 17.0 vs 22.1 μg/l; AUC 450.0 vs 672.3)
Nocturnal GH secretion was significantly impaired in CFS patients (peak 5.4 vs 9.0 μg/l; AUC 34.4 vs 67.4)
Serum prolactin levels were significantly elevated in CFS patients (7.4 vs 4.4 μg/l)
Serum TSH levels were significantly elevated in CFS patients (1.6 vs 1.0 mU/l)
Visceral fat mass was significantly higher in CFS patients (86.6 vs 51.5 cm²)
Inferred Conclusions
GH secretion is impaired in CFS across multiple stimulation conditions, particularly insulin-induced hypoglycemia and during nocturnal periods
Elevated prolactin and TSH suggest decreased dopaminergic tone in the brain
The relative GH deficiency may contribute to altered body composition (increased visceral fat) in ME/CFS patients
Pituitary-hormonal dysregulation appears to be a characteristic feature of ME/CFS
Remaining Questions
Does the impaired GH secretion directly cause ME/CFS symptoms, or is it a secondary consequence of the illness?
What This Study Does Not Prove
This study does not prove that GH deficiency causes ME/CFS symptoms or that GH replacement would benefit patients. The observation of normal IGF-I levels (GH's main functional mediator) raises questions about the clinical significance of the observed GH reduction. Correlation between hormone changes and visceral fat does not establish causation, and cross-sectional design prevents determination of whether hormonal changes precede symptom onset.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Contribute
Private, reviewed by a human. Not a public comment thread.